Compare KEYS & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEYS | BDX |
|---|---|---|
| Founded | 1939 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4B | 51.5B |
| IPO Year | 2014 | 1997 |
| Metric | KEYS | BDX |
|---|---|---|
| Price | $349.86 | $146.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $287.00 | $186.00 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ 39.89 | N/A |
| EPS | ★ 3.64 | 0.25 |
| Revenue | $5,375,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $25.49 | N/A |
| Revenue Next Year | $8.17 | $3.02 |
| P/E Ratio | ★ $93.33 | $589.64 |
| Revenue Growth | 7.95 | ★ 8.24 |
| 52 Week Low | $152.85 | $141.82 |
| 52 Week High | $370.18 | $213.08 |
| Indicator | KEYS | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 46.05 |
| Support Level | $325.62 | $142.48 |
| Resistance Level | $364.86 | $153.09 |
| Average True Range (ATR) | 12.91 | 3.25 |
| MACD | -0.72 | 0.33 |
| Stochastic Oscillator | 79.59 | 33.43 |
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.